DOCS Stock — Doximity Inc.

Doximity Inc. (DOCS)

Updated October 16, 2026.

DOCS is a Stock. Total return is -41.6% over the past 5.3 years, 134.2 points behind SPY at 92.6%.

Doximity operates a digital platform serving medical professionals in the United States, offering a personalized newsfeed with clinical content, workflow tools including AI-powered clinical documentation and scheduling, and telehealth capabilities for healthcare systems. The company generates revenue primarily from pharmaceutical manufacturers and health systems using its platform for sponsored content and services. The company does not currently have an established distribution schedule.

DOCS performance versus SPY

Price and return data through 2026-10-16.

Total return is -41.6% over the past 5.3 years, 134.2 points behind SPY at 92.6%. Over the past year its total return — price change plus distributions reinvested — is -54.0%. Its deepest 1-year drawdown was 73.7%.

DOCS key facts

Asset type

Stock

Asset class

Equity

Inception date

06/24/2021

Distribution frequency

None

Last close

$30.97 (as of 2026-10-16)

Market cap

$3,944,009,958

Average volume

3582686.0

Beta

1.216

Payout ratio

0.0%

P/E ratio

35.19

Forward P/E

19.7628

EPS

$0.88

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

DOCS risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 73.7%.

Who may consider DOCS — and who may not

It is a weaker fit for investors who need monthly cash flow (DOCS does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on DOCS

• All tickers starting with D

Tagged: Healthcare.

Frequently asked questions